Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1a/2a Trial of Sym015 in Advanced Solid Tumors
2016-003912-11Phase 2Completed
- Sponsor
- Symphogen
- Start
- Dec 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sym015 in Non-hematologic malignancy, sponsored by Symphogen. Primary endpoint: Documented objective response in Basket Cohort. Started Dec 2016; status: completed.
02
Drugs
sym015
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on 2016-003912-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003912-11.